FluoGuide
Danish based company developing surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | SEK12.1m | Post IPO Equity |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | - | 53 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | - | 41 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
FluoGuide is a biotechnology startup founded in 2018 that focuses on enhancing surgical outcomes for cancer patients. The company develops drugs that make cancer cells fluorescent, which helps surgeons see and remove tumors more precisely during operations. This innovation aims to reduce cancer recurrence and minimize surgical complications, ultimately lowering healthcare costs by decreasing the need for repeat hospital visits.
FluoGuide's flagship product, FG001, is designed to improve the accuracy of cancer surgeries by illuminating cancer cells. This product is currently in the clinical stage, meaning it is being tested in clinical trials to ensure its safety and effectiveness before it can be widely used.
The company primarily serves hospitals and surgical centers that perform cancer surgeries. Its market includes healthcare providers focused on improving surgical precision and patient outcomes. FluoGuide operates in the biotechnology and healthcare sectors, specifically targeting the surgical oncology market.
FluoGuide's business model involves developing and commercializing its fluorescent drugs. The company makes money by selling these drugs to hospitals and surgical centers. Additionally, it may generate revenue through partnerships, licensing agreements, and potentially from future products currently in development.
Recently, FluoGuide has been making strategic moves to position itself for growth. The company is transitioning from the Spotlight stock exchange to Nasdaq First North, which is expected to provide better trading opportunities for its shareholders. The leadership team, including CEO Peter Eriksen, brings extensive experience in growing and funding technology-intensive companies, which bodes well for FluoGuide's future prospects.
Keywords: biotechnology, cancer surgery, fluorescent drugs, FG001, healthcare, surgical precision, clinical trials, Nasdaq First North, innovation, patient outcomes.